SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging following positive Phase 3 trial results for its personalized mRNA cancer vaccine in high-risk melanoma patients, marking a significant clinical milestone that has triggered widespread speculation about a massive short squeeze. Community sentiment is electric as investors weigh the potential for a platform-wide breakthrough in oncology against concerns over the stock's parabolic move and the sustainability of its current valuation.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's stock is trending amid intense community speculation regarding a potential buyout by Nelson Peltz, with investors betting on a short squeeze due to high short interest and institutional accumulation. Traders are actively monitoring the stock for a formal announcement, focusing on the potential for a significant premium while bracing for volatile price action leading into the weekend.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a monumental custom AI chip agreement with Google that includes a multibillion-dollar warrant deal, positioning the company as a key player in the TPU ecosystem. While this catalyst has sparked significant interest, the stock is also experiencing intense volatility and profit-taking, fueling active debate among traders over whether this partnership justifies current valuations or if the stock remains susceptible to recurring sell-offs.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging as investors cheer building commercial momentum for Amtagvi and renewed optimism regarding the company's long-term pipeline, specifically upcoming data readouts in lung cancer. The community is actively discussing a potential short squeeze given the substantial short interest and heavy trading volume, with many bulls viewing current price levels as a fundamental re-rating opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin remains the focal point of community discussion as traders monitor crucial support levels while anticipating upcoming regulatory updates and institutional developments. Market participants are actively debating the asset's decoupling from broader equities, with many expressing optimism about a potential rotation into crypto as broader market volatility persists.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally around the company's progress toward a Q4 BLA submission for its prostate cancer therapy, bolstered by strong institutional accumulation and anticipation of upcoming data at the ASTRO meeting. The community is actively discussing the stock's potential for a significant M&A event or strategic partnership, driven by its multi-asset platform and robust cash position extending into 2028.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is currently trending due to intense volatility and investor frustration as the stock consistently lags behind sector peers despite high-profile infrastructure contracts. The community is actively debating the impact of institutional ownership, persistent short-selling pressure, and the absence of insider buying, with sentiment split between long-term confidence in data center expansion and short-term disillusionment with the stock's poor relative price performance.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is currently trending following a successful Phase 3 trial result for its personalized cancer vaccine in combination with Keytruda, which marks a significant milestone for mRNA-based cancer therapies. The community is actively discussing the stock's clinical validation, potential long-term benefits for the Keytruda franchise, and its broader impact on the oncology sector.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is facing heightened investor frustration and volatility as the stock struggles with a sharp pullback, leading to intense community debate over whether this represents a manipulation-driven "dip" or a structural breakdown. While some bulls are aggressively buying the decline and pointing to the company's Texas power infrastructure pipeline as a long-term catalyst, others are expressing concern over the sector's regulatory headwinds and erratic price action.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the community debates the stock's future ahead of earnings, with intense speculation focused on whether management will announce new partnership deals or licensing progress for its Matrix-M platform. Investors are expressing frustration over the lack of transparency, while many actively discuss whether the current stock price presents an accumulation opportunity or suggests a long-term breakdown in value.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RBBN
Share Price: $2.56

Contract Selected: Jan 15, 2027 $2.5 Calls

Buy Zone: $0.42 – $0.53
Target Zone: $0.74 – $0.90
Potential Upside: 63% ROI

Time to Expiration: 210 Days | Updates via https://fxcapta.com/stockinfo/

Every trade is a home run. Over 96% win rate on all trades for the past two years, over 1,000,000+ total trades. Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial advice. Trading involves risk, and past performance is not indicative of future results.

Fxcapta

fxcapta.com

StockTwits Web

Ribbon Communications Inc - Ordinary Shares - New


Share Price: $2.56

Contract Selected: Jan 15, 2027 $2.5 Calls

Buy Zone: $0.42 – $0.53
Target Zone: $0.74 – $0.90
Potential Upside: 63% ROI

Time to Expiration: 210 Days | Updates via 